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Bacterial keratitis is a disease of the cornea characterized by pain, redness, inﬂammation, and opacity. Common causes of this
disease are Pseudomonas aeruginosa and Staphylococcus aureus. Animal models of keratitis have been used to elucidate both the
bacterial factors and the host inﬂammatory response involved in the disease. Reviewed herein are animal models of bacterial
keratitis and some of the key ﬁndings in the last several decades.
1.Introduction
The human eye is composed of mucosal surfaces, such as
the mucosal epithelium of the cornea, as well as interior
chambers, such as the vitreous humor, that are potential
targets of infection (Figure 1). Bacterial infections of the eye
can range from mild, self-limiting conjunctivitis to devas-
tating panophthalmitis involving the entire orbit. Infectious
diseases of the eye not only involve the eﬀects of bacterial
colonizationandvirulencefactorsbutalsothehostresponses
to the pathogen. This interplay between bacterium and host
often necessitates the use of live animal models for the
study of ocular infections and development of eﬃcacious
treatments.
Keratitis, a disease of the cornea, can result from direct
infection with viruses, bacteria, fungi, yeast, and amoebae
or from immune-related complications such as the sterile
keratitis associated with Lyme disease. Bacterial keratitis
can occur in a variety of mammals and can be caused by
multitudes of bacterial species. The most common species
that have been associated with bacterial keratitis in humans
intheUnitedStatesinthelast 50yearsorso arePseudomonas
aeruginosa (Figure 2)a n dStaphylococcus aureus (Figure 3).
Many of the epidemiological reports from India implicate
Streptococcus pneumoniae as the most frequent cause. The
diﬀerences observed in bacterial causes of keratitis in diﬀer-
ent regions and countries have sparked an interest in climate
as a possible factor in the disease.
Many manuscripts published in the ﬁrst half of the
twentieth century were studies of trachoma, an ocular
infection caused by Chlamydia trachomatis characterized
by conjunctivitis, swollen eyelids, and sometimes corneal
haze [1–4]. Other early studies of note were focused on
neonatal conjunctivitis and its treatment [5–7]a sw e l l
as gonococcal and tuberculous eye infections [7, 8]. The
majority of reports at that time were observational studies
of clinical cases and outcomes following treatment with
penicillin, sulphonamides, or newer antibiotics such as
tetracyclines and macrolides [1–3, 5, 9–14]. Since that time,
studies of ocular bacterial infections expanded to address the
mechanisms of pathogenesis and the inﬂammatory response
in a so-called “immune-privileged” site. Basic and clinical
researches leading to newer treatments and the development
ofnewersurgicaltechniqueshaveallowedfordecreasesinthe
i n c i d e n c eo fs o m ei n f e c t i o n s[ 15–17].
2. Rabbits andPseudomonas aeruginosa
The most commonly used strain of rabbits for bacterial
keratitis studies is the New Zealand White rabbit, although
Dutch-belted rabbits have also been used. One of the earlier
techniques of inducing Pseudomonas keratitis in the rabbit
was developed by Hessburg and coworkers [19], in which
a silk suture contaminated with the bacteria was passed
through the rabbit corneal stroma. This technique was later
used in the examination of Pseudomonas proteases that had
been known to cause massive destruction of the cornea
[20], and for antibiotic eﬃcacy against P. aeruginosa [21].
Kessler et al. [22] used the intrastromal injection model, in2 Journal of Biomedicine and Biotechnology
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Figure 1: Diagram of the human eye (illustration by Michael K.
Krider).
Figure 2:Pseudomonaskeratitisin theNew Zealandwhite rabbit25
hours after infection. Experimental keratitis was induced by intra-
corneal injection of 1000 colony-forming units of a clinical urine
isolate of P. aeruginosa according to the method of O’Callaghan’s
group[18].The arrowindicatestheedge ofapurulentcornealulcer.
which bacteria were injected directly within the cornea, to
test the proteolytic activity of heat-killed P. aeruginosa in
the rabbit cornea, and to examine the host response to the
heat-killed bacteria. They suggested not only that the host
produced a massive inﬂux of polymorphonuclear leukocytes
(PMNs) in response to the injection but also that the corneal
damage could be due to host-produced proteolytic enzymes,
now known to be host matrix metalloproteinases (MMPs).
The inﬂux of inﬂammatory cells has also been implicated
as a cause of host corneal disease severity in Pseudomonas
keratitis in the rabbit [23].
Numerous investigations using the rabbit cornea as a
model for studying Pseudomonas virulence factors have since
been published. For example, Iglewski et al. [24]i n j e c t e d
puriﬁed exotoxin A into corneas and observed toxic eﬀects
which were neutralized by antitoxin. Thibodeaux et al.
[25] transformed the genes for two P. aeruginosa virulence
factors, elastase and alkaline protease, into a species deemed
nonpathogenic in the rabbit eye, Pseudomonas putida.S i n c e
Figure 3: Staphylococcus keratitis in the New Zealand white rabbit
19 hours after infection. Experimental keratitis was induced by
intracorneal injection of 100 colony-forming units of methicillin-
resistant S. aureus (clinical blood specimen) according to the
method of O’Callaghan’s group [18]. The black arrow indicates the
presence of stromal inﬁltration, and the white arrow indicates the
edge of a large corneal epithelial erosion, which was stained with
ﬂuorescein for ease of visualization.
P. aeruginosa had been determined to increase production
of other proteases when a particular protease was deleted,
examining the role of a particular protease in keratitis
by genetic deletion was complicated. Transformation and
expression of single proteases into a nonpathogenic host
such as P. putida allowed the investigators to determine that
elastase wasimportant fortheproductionofcornealerosions
during P. aeruginosa keratitis [25].
Various antibiotics and novel therapies have been tested
against Pseudomonas in the rabbit using the intrastromal
method of inoculation [18, 26–41] as well as topical inocula-
tion [42]. Other modes of inoculation to produce keratitis
by P. aeruginosa include topical inoculation preceded by
corneal scratch [43–45], corneal abrasion [46], and mechan-
ical removal of the corneal epithelium [42]. Pseudomonas-
contaminated contact lenses have also been used in rabbits
[47–51].
Besides antibiotic studies, rabbits have been used in
a variety of immunization studies to determine whether
vaccination against particular bacteria or bacterial antigens
could provide protection against keratitis. Kreger et al. [52]
immunized rabbits against P. aeruginosa lipopolysaccharide
or puriﬁed proteases and then challenged their corneas with
bacteria. The immunizations providedprotectionagainst the
severity of Pseudomonas keratitis.
A corneal ﬂap model has also been developed for
P. aeruginosa to mimic surgical complications, such as
keratitis after laser-assisted in situ keratomileusis (LASIK).
Holzer et al. used Dutch-belted rabbits for several studies of
diﬀuse lamellar keratitis following corneal ﬂap surgery [53–
56]. These studies entailed creating a corneal ﬂap in the
rabbit eye, applying P. aeruginosa lipopolysaccharide to theJournal of Biomedicine and Biotechnology 3
area, and then examining the eye for inﬂammation both in
vivoand by histopathology.
3. Rabbitsand Staphylococcus aureus
S. aureus keratitis has not been reported to be achieved by
topical inoculation of the rabbit cornea without additional
manipulations such as the application of bacteria-soaked
contact lenses; therefore, the usual method to achieve
Staphylococcus keratitis is intracorneal injection. One of
the older S. aureus studies was an antibiotic eﬃcacy study
with intracorneal injections of bacteria and application of
topical antibiotic ointments to the eyes [57]. Kupferman and
Leibowitz [58] reported the intrastromal injection model
of keratitis in rabbits and showed this model to be highly
reproducible. These authors later used this model to test the
eﬃcacyoftopicalantibiotictherapyofS.aureuskeratitis[59]
and found that in vitro minimal inhibitory concentration
assays of the antibiotics they tested did not necessarily reﬂect
eﬃcacies of these drugs in the eye.M o r e o v e r ,t h e yc a u t i o n e d
that not all strains of S. aureus would necessarily have the
same sensitivities as the strain used in their study. Their
ﬁ n d i n g sc o n t i n u et ob er e l e v a n tt od a t e .
The rabbit model of S. aureus keratitis is continually
used to study antimicrobial and/or antipathological com-
pounds [18, 30, 32–34, 36, 40, 41, 60–83]a sw e l la sh o s t
factors involved in the disease [84–87]. One of the most
signiﬁcant ﬁndings regarding S. aureus keratitis using the
rabbitintracornealmodelwasthatalpha-toxinwasthemajor
bacterial virulence factor responsible for disease severity
[88–91]. Moreover, immunization against alpha-toxin was
protective against S. aureus keratitis [92], and treatment of
infected corneas with cholesterol conjugated to cyclodextrin
as a means to inhibit alpha-toxin was able to signiﬁcantly
decrease disease severity [80].
Alternatives to the intrastromal model include soaking
contact lenses in S. aureus prior to placement on wounded
rabbit corneas [84, 93–95] and induction of a post-LASIK
model of keratitis in which S. aureus was inoculated under-
neathrabbitcornealﬂapsthatmimicLASIKsurgery[96]and
other corneal ﬂap models [97–99].
4.Mice and Pseudomonas aeruginosa
The advantage of the rabbit as a model for bacterial keratitis
is that its eyes are large like human eyes so several disease
parameters can be assessed. One such scale involves the
scoring of seven parameters such that a maximum disease
score would be 28 [100]. Mice have smaller eyes and are
often assigned disease scores up to a maximum of 4 [101]
b e c a u s eo ff e w e rp a r a m e t e r st h a ta r ea b l et ob ea s s e s s e d .
For example, conjunctival redness and the presence of ﬁbrin
in the anterior chamber can be visualized in the rabbit.
However, mice have other advantages as models for bacterial
keratitis. There are numerous strains of inbred and outbred
mice, a multitude of commercially available reagents with
which to analyze mouse-speciﬁc factors, and the availability
of genetically modiﬁed mice.
Gerke and Magliocco [102]ﬁ r s tr e p o r t e du s i n gt h e
mouse as amodelfor Pseudomonas aeruginosa keratitis.They
used diﬀerent methods of corneal wounding prior to topical
inoculation to achieve infection: incision (3 deep scratches
that did not penetrate into the anterior chamber), a 2mm
surface scratch, and needle puncture. They also performed
direct intrastromal injection of bacteria and determined that
the incision and injection modes were most consistent with
respect to pathology. To date, the majority of mouse corneal
inoculations with P. aeruginosa have been by topical scratch
of the cornea followed by dropping the bacteria onto the eye.
Mice have been used for immunization studies for the
possible development of alternative prophylaxes and thera-
pies of P. aeruginosa keratitis. In one such study, mice were
immunized with whole P. aeruginosa cells by intraperitoneal
ororalroute,andtheircorneasweresubsequentlychallenged
[103]. Monovalent and multivalent vaccines were used, and
it was found that intraperitoneal immunization with the
multivalent vaccine worked the best. These authors pointed
to another report that was published in 1927 that tested
Pseudomonas keratitis in vivo and alluded to the potential for
protection against keratitis by vaccination [104].
Immunizations of mice with Pseudomonas aeruginosa
protease and elastase toxoids, as well as the common O-
antigen, were able to protect against keratitis [105, 106].
Moreover, passive administration of rabbit antisera to mice
[52, 106], or passive immunization of mice with mono-
clonal antibodies speciﬁc for Pseudomonas outer membrane
proteins [107], was able to successfully treat Pseudomonas
keratitis. Zaidi et al. [108] demonstrated protection against
Pseudomonas keratitis by active and passive immunization of
live attenuated bacteria in C3H/HeN mice.
Mice have also been used in therapy eﬃcacy studies
of antibiotics and other potential antimicrobial compounds
[109, 110]. Hobden’s group recently showed that nona-D-
arginine amide was bactericidal to P. aeruginosa and exerted
anti-inﬂammatory eﬀectsin the infected mouse cornea [111,
112]. Kumar et al. [113] applied ﬂagellin, a bacterial ﬂagellar
protein and an agonist of toll-like receptor 5 (TLR5), to the
c o r n e a so fB 6m i c ea n df o u n dt h a ti tp r o t e c t e dt h ec o r n e a s
fromseverityofdisease andbacterialloads. Human tearﬂuid
has also been found to protect against Pseudomonas keratitis
in C57/BL6 mice [114]. Other novel therapies of interest
usingthismodelarecaspase-1inhibitor[115],silencingRNA
molecules [116, 117], interleukin-6 (IL-6) [118], Spantide 1
[119], chemokine antibodies [120], cyclodextrin [121], and
topical drops of alginate antibody [122].
Other studies of note involving Pseudomonas in the
mouse model of keratitis include ﬁndings regarding the
invasive potential of P. aeruginosa. Fleiszig et al. [123]ﬁ r s t
demonstrated that some strains of Pseudomonas were able
to invade mouse corneal cells in vivo and subsequently
showed that P. aeruginosa multiplied within the cells [124].
Invasive strains were found to produce type III secreted
exoproteins that enabled internalization of the bacteria into
mouse corneal epithelial cells [125]. Fleiszig’s group has
also examined alternative methods of corneal infection in
the mouse. One such method involved a modiﬁcation of
the topical scratch in which the epithelium was allowed to4 Journal of Biomedicine and Biotechnology
partially heal after the scratch before inoculation with P.
aeruginosa [126].Incontrastto theinvasive strains, cytotoxic
strains have been shown to secrete several proteases that
damage corneal tissue or induce the host immune response
in the mouse model [127–130].
Prior to the development and use of transgenic animal
models, studies on the host involvement in keratitis were
often focused on the diﬀerences between mouse strains,
elderly versus young mice, or drug-induced alterations in
animals. Hazlett et al. [131] showed that administration
of cyclophosphamide to mice caused Pseudomonas corneal
infection to spread and become systemic, conﬁrming pre-
vious suspicions that immunocompromised cancer patients
were at a higher risk for systemic infection following Pseu-
domonas ocular infections. This same research group also
examined the diﬀerences in pathogenicity of Pseudomonas
keratitis in a strain of mouse that was determined to be
“susceptible” to corneal infection (C57BL/6J, or T helper cell
type1responder)andastraindeterminedtobe“resistant” to
corneal infection (DBA/2J) [132]. The susceptible strain was
shown to have a decreased immune response to the bacteria
as measured by a reduction in inﬂammatory cells compared
to the resistant strain. Aged outbred mice with decreased
PMN response to corneal infection with P. aeruginosa were
also suggested to be less able to have restored corneal
claritythantheiryoungcounterpartsduetodelayedbacterial
clearance [133, 134]. However, the presence of inﬂammatory
cells has also been implicated as a cause of host corneal
disease severity in Pseudomonas keratitis in the mouse
[135–137]. These studies of general inﬂammatory responses
to Pseudomonas keratitis, plus numerous others including
analyses of cytokine expression, host MMP expression, and
T-cell-mediated immune responses, have been followed by
many studies with other species of bacteria as well as other
strains of mice.
5.Mice and Staphylococcus aureus
O’Callaghan’s group was the ﬁrst to report a mouse model
of S. aureus keratitis and showed that, similar to Pseu-
domonas keratitis, certain strains of mice were susceptible
(BALB/c and A/J) to infection whereas others were resistant
(C57BL/6) [138]. These investigators also showed that aged
mice, like humans, were more susceptible to severe keratitis
by S. aureus thanyoung mice [139], and that S. aureus alpha-
toxin was responsible for much of the damage observed
in the disease [140]. Other researchers have made slight
modiﬁcations to the mouse model, such as breaking up the
tear ﬁlm prior to inoculation [141], or using a trephine for
corneal scariﬁcation and inoculating with dead bacteria to
observe inﬂammation [142].
6.GeneticallyModiﬁedMice
The advent of genetic modiﬁcation of rodents has been
revolutionary in examinations of the role of the host in
bacterial keratitis. Mice in which speciﬁc genes have been
deleted, altered, or alternatively controlled have been used
in infection models to determine the host factors involved
in disease. Most of the studies to date have used mice
deﬁcient in cytokines and other immune factors, such as
toll-like receptors (TLRs). TLRs are present on or in host
cells such as macrophages and epithelial cells and respond to
pathogen-associated molecular patterns (PAMPs), triggering
a signaling cascade that ultimately results in up- or down-
regulation of inﬂammatory molecules such as cytokines.
Pseudomonas keratitis studies using genetically modiﬁed
mice have yielded information regarding the host response
to this bacterium. Cole et al. [143]u s e di n t e r l e u k i n - 1 0
(IL-10) deﬁcient mice to show that IL-10 was important
in controlling inﬂammation in the cornea in response to
P. aeruginosa. This group also used interleukin-4 (IL-4)
deﬁcient mice [144] and interleukin-6 (IL-6) deﬁcient mice
[145]t os h o was i m i l a re ﬀect for IL-4 and IL-6 in S. aureus
keratitis. Another study by Willcox and colleagues with mice
lacking the gene for CXC chemokine receptor 2 showed
that the host CXC chemokine receptor 2 was crucial for
inﬁltration of PMNs into the eye and subsequent bacterial
killing [146].
Genetic knockouts other than speciﬁc cytokines and
chemokines have been investigated. Huang showed the
importance of TLR4 in host resistance to Pseudomonas
[147]. Likewise, mice deﬁcient in MyD88, a TLR signaling
molecule, had reduced immune cell recruitment to the
eye in response to P. aeruginosa but had higher bacterial
burden and developed systemic infections [148]. Hazlett’s
group used caspase-1 deﬁcient mice to show that caspase-
1 was important for the inﬂammation observed during
keratitis [149] and matrix metalloproteinase-9 (MMP-9)
deﬁcient mice to show that MMP-9 assists Pseudomonas
keratitis by degrading corneal collagen and upregulating
proinﬂammatory cytokines [150]. These investigators also
recently showed a role for Fas ligand in the disease [151].
Recently, Pearlman’s group [152]f o u n dt h a tc o r n e a l
macrophages were the predominant cell type in the cornea
that expressed three TLRs of interest. The overall ﬁnd-
ing of the study was that activation of speciﬁc TLRs in
the cornea by P. aeruginosa resulted in transcription of
chemokines responsible for neutrophil recruitment to the
cornea, and that this recruitment was responsible for both
the inﬂammatory damage observed in the eye as well as
the killing of the infecting bacteria. Likewise, macrophage
migration inhibitory factor (MIF), when deleted from the
mouse genome, results in a severe inﬂammatory response to
Pseudomonas in the cornea [153]. Peptidoglycan recognition
proteins, which are similar to TLRs in that they recognize
PAMPs, have also been found to be important for innate
immunity to Pseudomonas keratitis [154]. A role for host
defensins has also been addressed for P. aeruginosa keratitis
using cathelicidin deﬁcient mice [155].
7.Other Animals
In 1975, Davis and Chandler reported an improved method
of examining and quantitating Pseudomonas keratitis using
th eg u i n e ap i ga sam o d e l[ 156]. One ofthe foci of thisreportJournal of Biomedicine and Biotechnology 5
was the use of intracorneal injection of bacteria so that the
inoculumwould be as precise aspossible. These investigators
also used a scoring system for the disease severity and
were able to quantitate the bacterial load from the corneas
by plating dilutions of infected homogenized corneas onto
bacterial growth medium. This method was determined to
be highly reproducible and has since been used by numerous
investigators, whether inguinea pigsor otheranimals such as
rabbits. Davis and colleagues also used the guinea pig model
for S. aureus keratitis [157].
Guinea pigs have also been used to study the role of
antibacterial or anti-inﬂammatory agents in Pseudomonas
keratitis [158–160] and contact-lens-related keratitis caused
by P. aeruginosa [161]. Contact lenses were contaminated
with the bacteria and then worn by guinea pigs for up to 48
hourstosimulateextendedcontactlenswearbyhumans.The
animals developed keratitis, or in some cases, a condition
called contact-lens-induced acute red eye (CLARE) [161].
This research group has also used the guinea pig contact lens
model to analyze the protective eﬀect of melimine coating
of contact lenses against S. aureus and P. aeruginosa [95].
A similar method to examine P. aeruginosa contamination
of contact lenses designed for orthokeratology was reported
using cats [162].
Rats have also been used in bacterial keratitis studies,
and it is not apparent whether the strain of rat is important
because diﬀerent strains were successfully used for diﬀer-
ent reports. The method of topical corneal scratch and
inoculation showed that the rat lacrimal gland responds
to Pseudomonas corneal infection [163]. The intrastromal
injection model has been used with rats to test whether
amniotic membrane transplantation could aid in corneal
healing following infection with S.aureus, and this technique
wasfoundtobeusefulasadjuncttherapytoantibiotics[164].
Another infection model for rats has been the infection by
the wearing of contaminated contact lenses [165]. A recent
investigation determined that rats developed Pseudomonas
keratitis after wearing contaminated contact lenses, and
that transfer of the lenses to na¨ ıve rats caused transfer of
the disease [166]. Other studies include antibiotic eﬃcacy
studies [167–169] and analysis of vitamin A deﬁciency and
the corresponding susceptibility to Pseudomonas keratitis
[170].
Mammals other than humans, in addition to being
used as models, are potential victims of bacterial keratitis.
For example, infectious bovine keratoconjunctivitis, usually
caused by Moraxella bovis, is a major health problem in
cattle. Pseudomonas, to name one genus, is a cause of
keratitis in horses and dogs. Cats can also acquire bacterial
keratitis,althoughlessfrequentlythandogs.Numerousother
mammals can develop keratitis, underscoring the prevalence
of bacteria able to cause pathogenesis in the eye.
8.Limitationsof Animal Models
Animals, particularly rabbits and mice, have been demon-
strated to be useful models for studying bacterial keratitis.
Some disadvantages exist, however, when using species that
have characteristics diﬀerent from humans. One of the most
obvious diﬀerences is that most of the animals used as
models are inbred. The advantage of using inbred animals
is experimental consistency; however, inbred animals do
not represent the human population as well as outbred
animals. Less obvious diﬀerences are speciﬁc anatomical
features, tissue composition, and various functions of ocular
components in animals and humans. Humans havea corneal
size of approximately 11mm in diameter, whereas rabbits
and mice have corneal sizes of about 13 and 2.2–3.5mm,
respectively [171, 172]. Corneal thickness is greater for
humans than rabbits and mice, and the blink interval for
humans is approximately 2.8 seconds whereas the interval
f o rr a b b i t sa n dm i c ei so v e r3 0s e c o n d s[ 171]. Rabbits have a
nictitating membranewhereas humans and micedonot.The
arrangement of corneal collagen [171]a n dt h ep r o p e r t i e so f
corneal epithelial cells [173]a r ed i ﬀerent between rabbits,
mice, and humans, which could produce alternate reactions
of the cornea to invading pathogens. Likewise, the corneal
epithelial basement membrane in humans is a network of
ﬁbers resembling a bird’s nest, whereas that of the rabbit’s is
straight and ﬂat. The anterior, collagen-rich banded portion
of Descemet’s membrane, which is the basement membrane
of the corneal endothelium, appears organized in a pattern
in humans but disorganized in rabbits [174]. Descemet’s
and Bowman’s membranes are also substantially thinner in
r a b b i t sa n dm i c et h a ni nh u m a n s[ 175]. Mouse corneas
have a higher ratio of corneal epithelial cells to stroma than
humans and more cell layers in the corneal epithelium[172].
Recently, confocal microscopy has detected more diﬀerences
between species, such as subcellular diﬀerences between
keratocytes of rabbits and mice [176]. Corneal proteins are
also diﬀerentially present; for example, mice have abundant
amounts of actin in their corneal epithelial cells whereas
rabbits and humans do not [173]. All of these anatomical
diﬀerences, as well as the blink intervals, have an eﬀect on
bacterial adherence and possible invasion, susceptibility to
bacterial enzymes and other virulence factors, and availabil-
ity of host defense molecules in the tear ﬁlm.
Featuresoutsideof thecornea canaccount fordiscrepan-
cies between the way humans and animals respond to ocular
bacterial infections. The lacrimal gland, which is involved in
tear secretion, is diﬀerent for humans, rabbits, and rodents
[177]. Compounding this diﬀerence is the vast gap in blink
intervals between humans, rabbits, and mice as described
above [171]. Not only is the architecture of the lacrimal
gland diﬀerent between these species, but also is function.
For example, lysozyme is a paramount protein produced by
thehumanlacrimal glandbutisnotaspronouncedinrabbits
and mice. This diﬀerence is important to note because
lysozyme is an enzyme that damages bacterial cells walls.
Other diﬀerences in lacrimal gland functions are electrolyte
secretion, production of lipid-binding proteins, secretory
IgA and secretory component secretion, and cytokine and
growthfactorsecretion[177].Manyocularsurface mucinsin
humans terminate in sialic acids whereas those from rabbits
terminate in 1-2 fucose or alpha-1-3 N-acetylgalactosamine
[178]. Since bacteria produce enzymes which cleave speciﬁc
residues in the host, studies of the eﬀects of bacterial6 Journal of Biomedicine and Biotechnology
virulence in animals could yield results that necessitate
cautious interpretation.
9.Conclusion
Infection of the cornea with bacterial pathogens such as
P. aeruginosa and S. aureus can result in loss of vision
due to the damage caused by the disease. This damage is
attributed not only to bacterial factors but also to host
immune factors. Therefore, models of bacterial keratitis
have been developed in animals to analyze the disease from
both the bacterial aspect and the host aspect. Despite the
diﬀerences between human and animal characteristic that
are involved in bacterial keratitis, the use of animal models
has contributed to the understanding of this disease and
the discovery of more eﬀective treatments that may prevent
corneal damage.
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